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Treating uveitis aims to prevent the development of ocular structural changes related 
to intraocular inflammation that could otherwise lead to vision loss. Inflammation 
control is achieved with immunosuppressive drugs, primarily corticosteroids, and for 
many years has relied on these, particularly in cases with concomitant systemic 
diseases or bilateral uveitis.1 While they are effective in controlling the inflammation 
many patients do not have systemic involvement and are unkeen to take systemic 
treatment. Direct access to the intraocular space means the eye is an ideal organ for 
local therapy, achieving high drug concentration on target. Local therapeutic options 
for the management of sight threatening non-infectious uveitis (NIU) include 
corticosteroids, methotrexate, anti-vascular endothelial growth factor (anti-VEGF) 
and more recently intravitreal biologics. The increased ability of these agents to 
sustain inflammatory control, though requiring repeat drug administrations, can help 
reduce the dose of systemic immunosuppression while maintaining a no 
inflammation state and preserving vision in such vision threatening conditions. 
 
The Multicentre Uveitis Steroid Treatment trial (MUST) is a multi-national trial, which 
was established as a prospective interventional study to compare local and systemic 
treatment for NIU. It examined the effect of systemic immunosuppression treatment 
on long term control of NIU with long acting local therapy in the form of a surgically 
inserted fluocinolone acetonide implant (Retisert®, Bausch and Lomb, Bridgewater, 
New Jersey), reported to maintain a constant intravitreal level of corticosteroids up to 
30 months. The interventional trial ran for 24 months, with 255 patients (479 eyes 
with uveitis) randomized to either systemic immunosuppression or a fluocinolone 
implant and were further followed for an additional 5 years as part of an 
observational study. The primary results demonstrated that at 24 months the implant 
resulted in comparable visual improvement to systemic immunosuppression with 
greater inflammatory control, and macular edema (ME) resolving in two thirds of 
eyes from both groups.2 Interestingly, over 60% of eyes treated systemically still 
required at least one supplemental local steroid injection.3 These trends remained 
stable throughout the next thirty months and were only lost at seven years follow-up, 
when eyes treated systemically showed a greater visual benefit of 7.2 letters.4 Eyes 
receiving the implants had a greater likelihood of developing ocular side effects, with 
90% of phakic eyes requiring cataract surgery and 45% underwent surgery to control 
raised IOP. However, the visual function remained comparable and many patients 
were disease free for many years without the need for additional treatment. The 
injectable fluocinolone inserts (Iluvien®, Alimera sciences, Aldershot, UK) avoid the 
need for surgery, provide long-term inflammatory control and possibly a smaller risk 
of raised IOP.5  
 
Periocular corticosteroid injections and Intravitreal triamcinolone acetonide injections 
(IVTA) are widely used in the treatment of ocular inflammatory disorders, reducing 
macular edema (ME) and vitritis. These procedures are relatively easy and safe with 
an efficacy of up to 72.7% of the eyes achieving complete control of inflammation by 
six months and half gaining significant visual improvement.6, 7 Their effect lasts up to 
6 and 12 weeks for periocular and IVTA injections, respectively, at which point they 
can be repeated with similar effect. Cataract and glaucoma are the main 
complications associated with these approaches and the risk of developing visually 
significant cataract requiring surgery is reported to reach 100% of eyes receiving ≥4 
repeated IVTA injections. This short duration of action and ocular side effect limits 
their use as long term treatment options, but they remain a useful method of 
achieving rapid local control of uveitis. 
The dexamethasone implant (Ozurdex®, Allergan, Irvine CA) has been licensed for 
the treatment of uveitis, offering a sustain release treatment option that may have a 
reduced risk of ocular complications compared to other local corticosteroids.7,8 The 
HURON trial demonstrated that following a single implantation, treated eyes were 
more likely to achieve inflammatory control and improved vision than untreated 
eyes.9 In both adults and children the effect lasts for several months and can then be 
repeated as needed.8 The risk of developing cataract and glaucoma is relatively low, 
with the majority of patients not requiring surgical intervention. The addition of local 
treatment as an adjunctive to systemic immunosuppression in young patients can 
help reduce their risk of developing systemic side effects related to systemic 
corticosteroids or long term use of steroid sparing agents.10 With an extended 
duration these patients could have long periods with good inflammatory control and 
no additional treatment. To clarify the place of each of these agents as treatment 
options for NIU the PeriOcular and INTravitreal corticosteroids for uveitic macular 
edema (POINT) Trial is an ongoing multicenter, randomized trial designed to 
compare the relative efficacy of periocular triamcinolone (Kenalog®, Bristol-Myers 
Squibb Company, Princeton, NJ), IVTA and the intravitreal dexamethasone implant. 
The trial will include 267 patients with uveitic ME randomized to one of the three 
treatment arms and will compare the percent change in central retinal thickness from 
baseline to the 8 week visit, duration of effect, change in visual acuity and the need 
for additional injections by 24 weeks for each of these treatment options. 
  
Intravitreal methotrexate injections (400µg/0.1 mL) may be considered an alternative 
in refractory cases. Though there are few studies that examined this treatment option 
it seems to offer a duration of effect of up to four months and a reduced risk of ocular 
hypertension.11-13 It has been reported that some of the treated eyes might even 
achieve a longer remission suggesting it may be a suitable option for glaucomatous 
patients or those with a history of steroid-induced ocular hypertension.  
 
The rationale for using intravitreal anti-VEGF drugs for treating NIU relates to 
blocking VEGF, restricting the induction of pro-inflammatory cytokines and reversing 
increased vascular permeability. Anti-VEGF is considered as treatment option mainly 
for refractory inflammatory ME, neovascularization and choroidal neovascular 
membrane.  Small series studies suggest that using anti-VEGFs in eyes with uveitic 
ME can lead to a reduction in ME and improved vision, however the current level of 
evidence is regarded as low quality, lacking a conclusive comparison to other 
options, such as intravitreal corticosteroids. The mechanism of action of these drugs 
limits their effect as anti-inflammatory agents and possibly restricts their use only to 
selective cases of refractory ME in otherwise non-active uveitis. The multicenter, 
Mcular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial 
is an ongoing randomized prospective study to compare the relative efficacy and 
safety over six months of intravitreal methotrexate, ranibizumab, and the 
dexamethasone implant for persistent uveitic ME. The trial includes 240 patients 
randomized to the three treatment arms and will compare the percent change in CRT 
from the baseline to the 12 week visit, improvement in vision and adverse events. 
 
Anti tumor necrosis factor drugs are taking on a prominent role in controlling uveitis, 
with adalimumab recently approved in the USA and Europe for treatment of NIU not 
responding to corticosteroids and at least one additional immunosuppression agent. 
The intravitreal use of these drugs has been the focus of several studies with 
conflicting results. While small prospective studies have demonstrated improved 
visual acuity and inflammatory control for both intravitreal infliximab14  and 
adalimumab,15 there is a reported increased risk of persistent ME and an intra-retinal 
immunogenic reaction.16 The efficacy of intravitreal sirolimus was examined in the 
Sirolimus study Assessing double-masKed Uveitis tReAtment (SAKURA) Study,17 
and found that those receiving an intravitreal dose of 440μg demonstrated a 
significant reduction in vitreous haze and ocular inflammation, maintained good 
visual outcome and in 77% of cases were able to taper off systemic corticosteroids. 
  
Local therapy, while not without significant ocular complications, primarily cataract 
progression and raised intraocular pressure related to use of corticosteroids, can 
nevertheless provide lasting good control of intraocular inflammation and stabilize 
vision. The need to repeat these invasive procedures remains a limiting factor, 
particularly among young patients. However, long-lasting agents, office-based 
injection procedures and improved patient response make these an important tool to 
long-term control of and a disease free state in such young patients with a chronic 
disease. 
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